A comprehensive search was conducted across PubMed, Embase, and the Cochrane Library to identify studies comparing the cardiovascular and renal outcomes of SGLT2 inhibitors and GLP-1 RAs in patients with type 2 diabetes. This evidence concerns the gene GCG and type 2 diabetes mellitus.